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Abstract
Background: In clinical trials, pregnant women are potentially vulnerable, and the fetus is exposed to the
intervention. This study aimed to identify the reasons that led pregnant women at a high risk of premature delivery
to participate in a randomized clinical trial.
Methods: The women participating in the main trial were contacted by telephone postpartum and invited to
answer an open questionnaire in a cross-sectional study. Data were collected by telephone and analyzed using
thematic analysis. After the analysis categories were defined, all the answers were reviewed, categorized and
grouped. A descriptive summary of the content of each category was then made.
Results: Overall, 208 women from different geographical regions of the country agreed to participate. Four
categories were identified: 1) The risk of losing the baby; 2) A previous experience of premature delivery; 3) The role
of the doctor and other health professionals, and 4) The availability of quality medical care and free medication. The
main reason given for agreeing to participate was to reduce the risks associated with the baby being born
prematurely, particularly when the woman herself or someone close to her had already experienced premature
delivery. Other reasons were having received clear guidance and explanations from the doctor regarding
prematurity and about the study and being given the opportunity to receive free treatment with greater access to
the public healthcare system.
Conclusions: The decision to participate in a clinical trial is not easy, particularly when the individual is vulnerable
and in a critical situation as in the case of a pregnant woman at a high risk of delivering prematurely. Fears and
uncertainties regarding the pregnancy outcome, as well as the woman’s previous experiences and her awareness of
the actual risks she faces will affect her decision regarding whether or not to participate. Recruitment challenges
could be overcome by ensuring that the research team provides adequate information and support, thus creating a
bond with participants that would foster a sense of safety and trust in the study proposals.
Keywords: Pregnancy, Premature delivery, Clinical trial
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: katzleila@gmail.com
1Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife,
Pernambuco, Brazil
Full list of author information is available at the end of the article
Monteiro et al. BMC Pregnancy and Childbirth           (2019) 19:97 
https://doi.org/10.1186/s12884-019-2240-8
Background
Clinical trials are intended to generate medical and sci-
entific knowledge, contributing to the development of
more effective and at times more innovative treatments.
The willingness of patients to participate in a given clin-
ical trial is a sine qua non for that trial to be conducted.
However, it is exceedingly challenging to recruit preg-
nant women as study participants, and the gaps in exist-
ing knowledge on this group of women may serve as
motivation for them to participate in research [1, 2].
Pregnancy is considered a normal physiological state;
nevertheless, most women will use at least one pharma-
ceutical drug during pregnancy that they did not use pre-
viously, in addition to the vitamins and mineral
supplements required during that time [3]. In the United
States, approximately two out of every three pregnant
women are prescribed medicines during pregnancy. Pre-
scribing medication during pregnancy is often based on
limited scientific evidence insofar as the drug’s safety and
effectiveness are concerned [4]. Indeed, because most
studies are conducted with non-pregnant women, the data
generated may not apply in full to pregnant women [5].
Up to the 1990s, the United States Food and Drug Ad-
ministration (FDA) recommended that pregnant women
should be excluded from clinical trials for their own pro-
tection, the intention being to protect the fetus from the
risks involved in participating in scientific research [6].
At the same time, this attempt to protect the fetus was
offset by the risk of submitting pregnant women to treat-
ments approved in studies conducted exclusively with
non-pregnant women [5, 7].
Randomized clinical trials conducted in critical situa-
tions such as pregnancy are necessary in order to establish
the safety of the product under evaluation and to supply
scientific evidence of the outcome [8]. Pregnant women
have traditionally been recognized as a potentially vulner-
able population [9, 10]; therefore, it is particularly import-
ant that their experiences and perspectives, especially in
critical situations, are understood [11, 12].
Currently, the FDA permits and even encourages the re-
sponsible inclusion of pregnant women in clinical trials as
long as patient monitoring and safety is assured [13]. Never-
theless, there are still some limitations with respect to ran-
domized clinical trials involving pregnant women, since
these women are in a situation of vulnerability and because
the fetus will also receive the proposed intervention [14].
The experience of women regarding the use of pharma-
ceutical drugs during pregnancy and their adherence to
drug therapy are subjects that have seldom been evalu-
ated. In general, pregnant women tend not to comply with
drug therapy and/or to submit themselves to interventions
during pregnancy through fear that they will lose their
baby and/or that the treatment could cause undesirable ef-
fects on the fetus, even when the proposed treatment has
been shown to cause no harm [3]. Therefore, when invited
to participate in a clinical trial, the woman may withhold
consent if she believes that participation could represent a
risk to the baby or, conversely, she may feel pressured to
agree to interventions that could benefit the fetus [14].
This decision is made even more difficult when the study
involves high-risk pregnancies.
Various factors may interfere in the pregnant woman’s
decision to participate or not in scientific research. The
objective of the present study was to determine the rea-
sons given by pregnant women for participating in a
clinical trial and submitting themselves to interventions
during pregnancy.
Methods
This was a cross-sectional study based on the qualitative ana-
lysis of open questions used to evaluate women’s experience
of participating in the Pessary Plus Progesterone to Prevent
Preterm Birth (P5) Study (Trial registration RBR-3t8prz).
The P5 study
Briefly, the P5 randomized controlled trial involves women
at a high risk of preterm labor and has been ongoing since
July 2015 in 17 Brazilian centers. The principal objective is
to compare the efficacy of progesterone alone versus pro-
gesterone associated with cervical pessaries for the preven-
tion of preterm birth in pregnant women with a short
cervix. The study also aims to evaluate whether its results
will justify universal cervical length screening and deter-
mine a treatment policy for the Brazilian population.
Pregnant women with a short uterine cervix, i.e. cervical
length ≤ 30mm as assessed by transvaginal ultrasonog-
raphy screening at 18 to 22 weeks of pregnancy, are in-
vited to participate in the clinical trial in which they may
receive 200mg of vaginal micronized progesterone alone
or progesterone associated with a cervical pessary. Follow-
ing randomization, women are followed up until 10 weeks
after the infant’s birth to evaluate neonatal outcomes.
During recruitment to the clinical trial, patients are
given an explanation on the risk of prematurity and the
P5 study protocol. The woman should clearly under-
stand that participating in the study does not guarantee
a better gestational outcome, that she is free to decide
whether to participate, and that her decision will not
affect the treatment she and her child would receive at
the healthcare unit. The patients are provided with ex-
planations regarding the most common side effects of
using vaginal progesterone (constipation, nausea, vaginal
discharge) and the cervical pessary (intense vaginal dis-
charge, leucorrhea, vaginal pain, cervical necrosis and
painful intercourse). The information provided orally to
the patient and on the informed consent form is believed
to be sufficient to allow the women to reach a decision
regarding their participation in the study.
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The cross-sectional qualitative study
The present cross-sectional study was part of a strategy
within the P5 Study to identify barriers to developing a
treatment to prevent preterm birth. The main objective
was to obtain information on the experience of pregnant
women regarding medical management for the preven-
tion of preterm birth. This study also aimed to provide
further clarification regarding the barriers that exist
within the recruitment process and during the follow-up
of critically ill and vulnerable patients in a clinical trial.
For this purpose, a structured questionnaire containing
both open and closed questions was administered to
women who had completed the follow-up period of the
P5 study, which extended until July 2017, meaning that
all the women were interviewed 10 weeks after delivery.
Eligible women were contacted by telephone and invited
to participate in the cross-sectional study. For those who
did agree to participate, an appointment was made at a
convenient date and time for each woman. Since the inter-
views were conducted by telephone, informed consent
was given verbally, and the women’s agreement to partici-
pate in the study was recorded. The informed consent
form was read to the women invited to participate in the
study and they were given the opportunity to ask ques-
tions and clarify any doubts. When the women were satis-
fied with the information and with the answers they had
received, they were asked if they would agree to partici-
pate in the study and their consent was recorded.
The internal review boards of the University of Campinas
(UNICAMP) and the Instituto de Medicina Integral Professor
Fernando Figueira (IMIP) approved the study protocol under
reference numbers CAEE 5592.3016.1.0000.5404 and CAEE
3841.7114.0.2005.5201, respectively.
The 36-item questionnaire used in the cross-sectional
study included 8 open questions about the women’s experi-
ence of using a treatment to prevent prematurity (Additional
file 1). These questions were related to women’s understand-
ing of the doctor’s explanations, prematurity, risk perception,
experiences of her participation in the study, doubts about
whether it was appropriate for the woman to participate in
the study and her perception regarding the success of the
treatment provided. The questions were asked directly and
clearly.
The interviews were conducted in the Portuguese lan-
guage and lasted on average around 10 minutes. The
women’s answers were recorded and registered in a
digital version of the questionnaire, with the responses
to the open questions being transcribed ipsis litteris into
the database. The interviews were conducted between
January and July 2017 by investigators with experience
in this interview technique. For this article, which re-
ports on the reasons given by women for agreeing to
participate in a clinical trial, a qualitative analysis was
performed of two open questions directly linked to our
objectives: 1) What made you finally decide to undergo
the proposed treatment? and 2) In your opinion, did the
treatment work or not? Why?
The participants’ responses were analyzed until satur-
ation was reached. Data analysis was conducted according
to the guidelines proposed by Patton [15]. The text corre-
sponding to the two questions was read several times by
two of the investigators to identify the units of analysis in
the women’s answers that would meet the proposed objec-
tives. Based on the defined set of units of analysis, categor-
ies of analysis were then proposed. After the categories
had been defined, all the answers were read again, catego-
rized and grouped together. A descriptive summary of the
content of each category was then made.
This paper presents the results obtained for the fol-
lowing categories of analysis:
 The risk of losing the baby;
 A previous experience of premature delivery;
 The role of the doctor and other health
professionals;
 Quality medical care and free medication
Results
A total of 356 women were eligible for inclusion in the
study. Of these, 127 could not be contacted by telephone
and 21 refused to participate. Most of the women who
refused to participate gave no reason for doing so. Those
who did provide an explanation stated that the outcome
of their pregnancy had been negative.
Interviewers stopped asking the open questions when the
analysis reached saturation, which occurred at around 200
answers. Overall, 208 women with a mean age of 27.8 years
were interviewed. Of these, 63.1% reported having com-
pleted high school, while 19.4% had completed elementary
school, 15.0% had graduated from university and 2.4% had
completed postgraduate studies. Self-reported ethnicity re-
vealed that 39.8% of the women considered themselves
white, 9.2% black and 50.5% brown. The majority (79.3%)
stated that they lived with a partner. In addition, 22.8% of
the women had already been affected by prematurity and
94.1% had had a singleton pregnancy.
The risk of losing the baby
The main reason given by the women for agreeing to
participate in the study was their concern about the risk
of losing the baby. Their worry regarding the baby’s life
was expressed at various moments throughout the inter-
views, with many stating explicitly that they were afraid
of losing their baby, that participating in the study was
“the only way to save the baby”, “the only way out”, …
“my last chance”. They mentioned that they would do
anything available to prevent premature delivery and by
doing so prolong the pregnancy and “save the baby”.
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“I did it to try to keep the child, right. To avoid the
risk of having her too early or maybe even of losing
her before that” (Example 117699).
The fear and anxiety of experiencing a high-risk
pregnancy was a strong influence in the woman’s
decision to participate in the study. For some, this
fear was triggered by a previously unknown condi-
tion identified and explained by the healthcare pro-
fessional involved in the study. Learning of the
study’s existence and, consequently, of the treat-
ment aimed at avoiding premature delivery offered
the women new hope of being able to prolong their
pregnancy for as long as possible. For some women,
agreeing to participate meant protecting the baby,
making the pregnancy safer and thus increasing the
likelihood of a good outcome despite the fact that
the effects of the treatment were still unknown.
“Actually…when I discovered that I was
pregnant…. I had undergone insemination. I lost
one baby at three months but the other one went
on; so it was a much loved and longed for child.
I would never have given up. I would have gone
after a solution even if it were in another state,
another country, but I didn’t want to lose my
child” (Example 10).
One patient commented that she was afraid that if
she didn’t agree to participate in the study her baby
would be born prematurely. The role the mother as-
sumes as guardian of her fetus’s well-being is clear
from this comment, as is the responsibility she un-
dertakes with respect to the health of the fetus -
agreeing to participate in scientific research because
she is afraid that refusing to do so would place her
baby’s health at risk.
“Because I was afraid of not doing it and losing
the baby” (Example 117857).
Some of the women agreed to participate in the study
because they had other conditions that affected their risk
of premature delivery in addition to their diagnosis of a
short cervix, further increasing their likelihood of pre-
maturity.
“My cervix was short, but not that short. It was 29
[millimeters]…but I also had another risk factor
because I had a bicornuate uterus and I thought: “if I
have a risk factor and I can benefit from something
that is going to prevent my baby being born early,
then I’m going to agree to it” so I decided to accept”
(Example 119573).
A previous experience of premature delivery
For some women, previous negative experiences of pre-
mature delivery and/or gestational losses of their own or
of someone close to them made them fearful of experien-
cing another similar situation and this was the principal
motivating factor behind their decision to agree to the
treatment. The women expressed concern about having a
premature child because survival is low, because the baby
could suffer various health problems and might have to be
admitted to an intensive care unit (ICU). Some women
mentioned that prematurity could lead to complications
for the babies over the short- and long-term, requiring ex-
tensive periods in incubators in the neonatal ICU, and that
this was their reason for participating in the study. Even
women who had not experienced this personally but who
were close to people who had gone through such an ex-
perience were also affected by it.
“The other babies, it was hard having to see them in
the ICU, when the only thing I could do was watch
over them. So, I really wanted to have a pregnancy
that would go to term, to be able to leave the delivery
room with my baby. For that reason, I would have
done just about anything that they said would help,
no matter what” (Example 46).
“I decided first of all because I had my first pregnancy
and I lost a baby…in my second pregnancy, when I
knew I was pregnant again, my second baby was born
at 32 weeks, premature too, and he stayed in the ICU
for a month. When he (the doctor) told me that there
was this medicine to hold in the premature baby, I
decided to go for it. I knew there was a likelihood that
this third child of mine would be born prematurely
too, that it wouldn’t go the whole nine months. So,
with this medicine my baby went up to 36 weeks”
(Example 36).
The role of the doctor and other health professionals
The explanation given by the doctors regarding the diag-
nosis of short cervix and the proposed treatment influ-
enced the women’s decision to participate in the study.
Since they were fragile/vulnerable at that moment be-
cause of what they were going through, the role of the
doctor was crucial in the process of deciding whether to
participate in the study.
According to the women, the information provided by
the doctors was clear, comprehensive and given in such
a way that they were able to understand what was being
explained. The information provided included the ex-
planation that this was a research study and that agree-
ing to participate was no guarantee that the pregnancy
would successfully go to term. The women quoted the
Monteiro et al. BMC Pregnancy and Childbirth           (2019) 19:97 Page 4 of 9
doctors as saying that: “it was not definite that it [the
treatment] would actually work” and that… “it might not
be possible to maintain the pregnancy”.
The conversations between the doctors and the women
established a bond of trust between them. This made the
women feel more secure with respect to the problem they
were facing and the treatment that was being proposed,
thus enabling them to reach a conscious decision regard-
ing whether or not to participate in the study.
“In fact, the doctor’s explanation was very important
for me. He discussed all the possibilities with me and
made me feel safe…” (Example 37).
“Because in actual fact there was no conclusive
evidence that the treatment would actually work, but
I agreed to do it because if by doing so there was a
chance that my baby would be born at term, I wanted
to take advantage of it irrespective of anything else”
(Example 25).
Referral made by the doctor providing prenatal care
In some cases, it was the doctors providing prenatal care
who referred the women to the centers in which the P5
study was being conducted. These women mentioned that
their doctors considered the treatment to be safe and ef-
fective for avoiding premature delivery. In addition, cer-
tain women were referred because they had a history of a
previous high-risk pregnancy. Referral by the doctor pro-
viding prenatal care made these women feel safer and
more confident about agreeing to participate in the study.
When given a diagnosis of short cervix and when the risk
of premature delivery was explained to them, some
women, who had not been referred by their gynecologists,
called their doctors to ask their opinion on whether or not
to participate in the study.
“I realized that it would be better to ensure that my
pregnancy went to term and also because my doctor
had said that it is a very safe and effective method to
avoid the risk of premature delivery” (Example 1).
Quality medical care and free medication
Some women praised the care they received during their par-
ticipation in the study. They mentioned that it was quality
care provided by attentive professionals, who gave them the
information they needed in such a way that it was easily
understood. They were also given reassurance about the tests
to be carried out and also about the place in which the study
was being conducted. In addition, they received the treat-
ment free of charge. All these actions carried out by the re-
search team contributed towards reassuring the woman,
both with respect to her own participation and that of her
child. The possibility of easy access to treatment and
follow-up in the study center was also mentioned. Only
one patient considered that the information regarding the
high risk of prematurity given by the healthcare profes-
sional following the diagnosis of a short cervix was not
given in a humanized manner. She was very upset when
leaving the hospital and had no accompanying person
with her at the time. Nevertheless, she underwent the
treatment and considered it valid.
“Right from the very first consultation, they were very
clear with me and gave me lots of attention. So, I felt
that this was additional care that I was getting for my
child. They provided attention and monitoring that
we really need, irrespective of whether we have
private healthcare insurance or if we depend on the
National Health Service (SUS). The assurance that
they gave me was substantial, right from the very first
day” (Example 116345).
“For me it was marvelous [having participated in the
study]. I had no doubts whatsoever and I am just
grateful that I was given the opportunity to use the
pessary and progesterone” (Example 18).
Several of the women stated that one of the reasons for
having agreed to participate in the study was the fact
that it was free.
“It is a very [expensive] treatment…the devices, the
medication that is provided and everything. It’s very
expensive. So, it’s free healthcare, isn’t it? Both benefit
from it, right? It benefits those who are doing all this,
right, and I benefit from the study too”. (Example
116345).
Many of the women understood that the pessary was of-
fered as an alternative to cervical cerclage since it was
already too late to perform cerclage at that more ad-
vanced stage of their pregnancy. Those women agreed to
participate in the study because “it was the only option
available to me”. One patient reported a previous nega-
tive experience with cervical cerclage and for that reason
she decided to participate in the study.
“Because that was the most viable option”.
(Investigator: Most viable for what?). “To avoid the
risk of premature delivery and, since I was already at
an advanced stage, I couldn’t have cerclage anymore
so this was my only option” (Example 115301).
“Because I had undergone cervical cerclage previously
and it was very painful. So, I opted to insert the
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pessary because I thought it would be better…. I
thought that with the pessary I would be able to move
around easier, walk about. With my uterus sewn up, it
would be very painful for me” (Example 116005).
A few patients agreed to participate in the study to be
able to contribute to the development of scientific re-
search and help other mothers avoid premature delivery.
“Firstly, as a precaution; it would help avoid
premature delivery, but also to help your study get
answers, bearing in mind that this process is still
under evaluation. So, to be able to make my
contribution too and also to be monitored by a
professional” (Example 113499).
Discussion
For the great majority of the pregnant women participating
in this study, the main reason for agreeing to participate in
the P5 clinical trial was their fear of losing the pregnancy.
This fear was based not only on their current situation but
also on the women’s perceived risk based on a previous ex-
perience of premature delivery, either their own experience
or that of someone close to them. The information and in-
structions given by the health professional, together with
the trust they had in this professional, were also mentioned
as reasons behind the women’s decision to participate in
the study, as well as the opportunity to obtain easier access
to healthcare services.
For these women, participating in the study offered them
the possibility of protecting their babies. Faced with a situ-
ation that could expose the pregnancy to considerable risks,
these women agreed to participate in the study in the hope
of improving their child’s chances despite being told by the
study team that this was a research study and that there was
no guarantee that the treatment would improve the perinatal
outcome. However, it is true that a pregnant woman experi-
encing a critical situation and in a condition of vulnerability
places her hope and faith in the health professionals and the
treatment offered by them. Some women, therefore, may
have felt compelled to participate in the study because of
fears or doubts that not accepting the treatment would result
in harm to their child. Even so, other women who were iden-
tified at ultrasound screening as being at a high risk of pre-
maturity chose not to participate in the clinical trial because
they did not believe that the risk justified exposing them-
selves and their baby to an experimental treatment. Likewise,
a qualitative study reported that the principal motivation
given by pregnant women for having participated in a scien-
tific study was the possibility that it would benefit their baby
to some extent. Even knowing that it was an experimental
study, in general the mothers concluded that participating
would cause no harm and that this would, therefore, be the
best decision [8].
Previous studies, conducted to evaluate the motives that
lead pregnant women to withhold their consent to partici-
pate in clinical trials, showed that the risk of exposing them-
selves and their fetus to a treatment that is still undergoing
evaluation is deemed unacceptable to the women and repre-
sents a significant barrier to recruitment [16, 17]. In the
present study, few women expressed fear or misgivings re-
garding use of the cervical pessary, with this seldom being
given as a reason for not participating in the study. Since the
benefits of this treatment in preventing premature delivery
have yet to be confirmed and since the pessary is inserted
into the pregnant woman’s vagina, women may find it diffi-
cult to understand both the mechanism of action and the
pessary location. Such uncertainties may have weighed heav-
ily in their decision not to participate in the study. None of
the women reported fear or misgivings regarding the use of
progesterone. This could be explained by the fact that proges-
terone is already available on the market as a treatment for
premature delivery, and many women have already used it or
know other women who have done so; hence, it is already well
known to the patient as an established treatment.
Many women agreed to participate in the clinical trial
after talking to the healthcare professional. Based on the
information given to these women by the medical team
during screening and when their cervix was being mea-
sured, they became aware of their increased risk of pre-
maturity and the complications that could develop as
the result of premature delivery. The clear and detailed
way in which the information was provided, inspiring con-
fidence and a sense of security in the women and estab-
lishing a good doctor-patient relationship, was mentioned
several times by the women as being important factors
when deciding whether or not to participate in the study.
This shows the importance of the doctor-patient relation-
ship in the decision-making process, since the pregnant
woman begins to gain confidence in what is being pro-
posed. In addition, the pregnant woman also believes that
participating in the study will not result in any negative
consequences, since the health professional would clearly
not expose her to any risk. Similar findings were reported
in a qualitative study that evaluated 22 pregnant women
in premature labor participating in a clinical trial [8].
A multicenter study involving 3733 women found that
the principal motivating factor in the decision to partici-
pate in a clinical trial was how well the study was ex-
plained, while the risk of unknown side effects was the
principal barrier [17]. Similar findings were reported from
a qualitative study involving 296 pregnant women who
had refused to participate in a clinical trial involving the
use of dietary supplements. The conclusions of that study
were that the role of the research team is fundamental in
fostering the woman’s confidence in the study by ensuring
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that she clearly understands the risks and benefits associ-
ated with her participation and allowing her to feel lis-
tened to and supported. Implementing such actions would
increase participant recruitment [16]. Furthermore, a good
doctor-patient relationship creates a bond between the two
that will last throughout the entire study, increasing not only
recruitment but also compliance with the study follow-up.
This relationship between the P5 healthcare professionals
and the women represents a possible a source of bias and
may have influenced the patient’s perception of risk and the
need for treatment. The fact that some women who refused
to participate in this cross-sectional study stated that the out-
come of their pregnancy had been negative might suggest
the presence of bias, since more women whose pregnancy
outcomes were negative may have refused to participate.
This may constitute a limitation of the present study.
According to some patients, the fact that the doctor pro-
viding their prenatal care, who was not part of the P5 study
team, had given them information and recommended the
treatment was their reason for agreeing to participate in the
study, reinforcing the influence of the doctor’s opinion in the
decision-making process. A qualitative study that evaluated
22 patients participating in the ORACLE 1 and 2 clinical tri-
als involving pregnant women with a risk of infection found
that the principal factor influencing the woman’s decision to
participate in the study concerned the socio-emotional as-
pects involved in the relationship between the health profes-
sional and the patient [8]. The women considered that the
critical nature of the situation hampered their ability to ab-
sorb the information provided; nevertheless, they viewed the
information provided by the professional in writing or ver-
bally in a positive and favorable manner [18].
Therefore, the manner in which the information on the
clinical trial is presented to the woman, including the lan-
guage and terminology used, can affect her understanding of
the study [19], influencing her decision to participate in the
scientific research or not [20, 21]. In addition, it affects her
satisfaction during the study [22] and increases patients’ per-
ception of the competence of the professionals [23]. This
strong relationship found between the pregnant woman and
her obstetrician/gynecologist has already been reported in a
study conducted to compare factors affecting the decision of
the emergency patient regarding whether or not to partici-
pate in clinical trials in different areas of health. In that study,
a good doctor-patient relationship was considered one of the
main factors motivating the women to participate in research
in the field of obstetrics/gynecology, whereas one of the
major barriers was lack of trust in the doctor. This associ-
ation was not found to the same degree in other medical
specialties [24]. In the present study, the close bonding be-
tween the women and the healthcare providers was obvious
from the statements made by most of the patients, and this
could constitute a limitation of the study. Unfortunately, a
bias such as this is a common occurrence since the care and
the attention that clinical trial participants usually receive is
somewhat different.
For patients with a prior experience of prematurity, ei-
ther a personal experience or that of someone close to
them, the decision regarding whether or not to participate
in the study was strongly affected by this past experience.
Experiencing prematurity and the consequences associ-
ated with it such as the baby having to be admitted to an
ICU, sequelae in the newborn infant, and in the most se-
vere cases, the baby’s death, so marked these women that
when receiving a diagnosis of short cervix and being in-
formed of their increased risk of prematurity, these mem-
ories returned and were decisive in their agreement to
participate in the study. This process was associated with
parents’ psychological disorders and traumas, since the
parents were unprepared to deal with the stress caused by
the child’s clinical condition and the need for intensive
care [25]. When the outcome of their experience with pre-
maturity was poor, the women were clearly even more
eager to participate in the study, since in this study having
experienced a previous negative outcome generated even
more fear of losing another baby.
In the present study, the partner’s opinion was not
mentioned as a factor influencing the woman’s decision
regarding whether or not to participate in the study. The
women decided by themselves whether to participate in
the study or not, and this highlights their autonomy and
self-sufficiency in choosing what they believed to be cor-
rect for them and for their child when in a situation of
vulnerability such as pregnancy. In addition, the women
did not mention that participating in the study would
mean having access to a treatment for the prevention of
premature delivery (cervical pessary) that was not yet
available within the Brazilian National Health Service.
Conversely, results of another study showed that the preg-
nant women who agreed to participate in a clinical trial
did so because it appeared beneficial and the treatment of-
fered was not available to anyone outside the study [26].
Some of the women stated that being able to contribute
to science and help other women have their children was
yet another reason for them to agree to take part in the
study; however, it was not the principal motivating factor.
This has been mentioned in other studies, but in general
it is associated with the belief that it is acceptable to do so
in benefit of others as long as it involves no risk or harm
to the participant or her child [8, 16, 24].
Some of the women mentioned that gaining better ac-
cess to healthcare services weighed strongly in their deci-
sion to participate in the study. One study involving
pregnant women also found that women who agreed to
take part in a clinical trial tended to believe that they
would receive better care and have greater access to health
professionals and to the medical tests they would require
during pregnancy [8, 27, 28]. In developing countries such
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as Brazil, where access to public healthcare is often diffi-
cult and limited, participating in research could provide a
woman with treatment that she would not ordinarily have.
These women are able to access medical consultations,
tests and treatments much faster than they normally
would. In the case of the participants in the P5 study, the
women had greater access to ultrasonography and more
frequent medical consultations, including easier access to
doctors, who even gave the women their cellphone num-
ber so that they would be contactable at any time to an-
swer any questions. All this may also have influenced the
women’s satisfaction with the treatment and strengthened
the doctor-patient bond.
Interestingly, few patients refused to participate in the
present study. As these patients had been monitored prac-
tically throughout their entire pregnancy and also follow-
ing childbirth, they could have been expected to refuse to
participate in yet one more stage, including interviews,
particularly since another study reported that extended
patient follow-up proved to represent a barrier to partici-
pation in scientific research [17]. This result is probably
related to the manner in which the entire recruitment
process and follow-up was presented and offered to the
patient in the P5 study, providing comfort and a sense of
safety to such a degree that the women were happy to be
able to contribute in other stages of the study.
One of the strongpoints of the study refers to the sub-
stantial number of participants, which allowed adequate
categories of analysis to be established and the principal
barriers and reasons affecting the women’s decision to
participate in the study to emerge. Furthermore, evaluat-
ing what leads pregnant women in developing countries,
where education in health and knowledge regarding clin-
ical trials are limited, to participate in studies is interest-
ing and will certainly serve to guide the planning of
future projects.
In addition to the limitations already mentioned, there is
the fact that, although the women confirmed having under-
stood the information provided regarding the design of the
clinical trial and the entire protocol and follow-up, this was
not checked. The degree to which the candidate for inclusion
in a study understands how the study is to be conducted
could influence the number of individuals inclined to partici-
pate in the study. Additionally, the women were interviewed
some weeks or months following childbirth, which could
have affected their memory of the occurrences and, conse-
quently, their comments.
Conclusions
Deciding to participate in a clinical trial is not an easy deci-
sion, particularly when the individual in question is vulner-
able and in a critical situation as is the case of a pregnant
woman at high risk of delivering prematurely. The fears and
uncertainties regarding the future of the pregnancy will affect
her decision on whether or not to participate, as will her pre-
vious experiences and her awareness of the actual risks she
faces. New clinical trials should take this vulnerability into
consideration during the recruitment process, ensuring that
the approach taken by the health professional includes clear
and sufficient information that will allow the patient to feel
confident and at ease to decide whether or not to participate.
The role of the healthcare professional involved in the
woman’s prenatal care and in following her up during the
clinical trial is crucial in answering any questions she may
have regarding the risk to which she is exposed and, more-
over, regarding the entire study design and protocol that is
being proposed, thus enabling her to make a conscious
and safe decision. This doctor-patient communication will
play a pivotal role in constructing a bond that will con-
tinue throughout the entire study, increasing participant
satisfaction and facilitating follow-up.
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